Clinical Trial Update: Norepinephrine-targeted Therapy for Action Control in Parkinson Disease [Phase 4]

View source ↗

Summary

Phase 4 trial updating norepinephrine-targeted therapy for action control in Parkinson disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Parkinson Disease | Phase 4 | Status: COMPLETED | Results posted: 2020-01-27